Dr. Peter Grootenhuis is Senior Director Chemistry at Vertex in San Diego. Prior to joining Vertex in 2002, he worked at CombiChem-DuPont and Organon. At Vertex, Grootenhuis has been research project-leader in the areas of cystic fibrosis (CF) and sodium channel blockers for pain. He is co-inventor of two FDA approved drugs to treat CF (ivacaftor, lumacaftor) and five clinical candidates.
Grootenhuis received MSc and PhD degrees in chemistry at the Universities of Utrecht and Twente in the Netherlands. Subsequently, he performed post-doctoral studies in computational chemistry at UCSF (Prof. P. Kollman) followed by a short sabbatical with Prof. M. Karplus at Harvard University. Grootenhuis has co-authored >100 peer reviewed papers and is inventor of 65 U.S. patents.